The p53 tumor suppressor protein exerts most of its anti-tumor-igenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis, independent of transcriptional activity. Processing of p53 by caspases results in the generation of four cleavage products, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**EXPERIMENTAL PROCEDURES**

**Cell Culture and Drug Treatments**—Cell lines were grown as suggested by ATCC. Transfections were carried out by using Lipofectamine 2000 reagent (Invitrogen). Apoptosis was assessed by flow cytometry using annexin V-propidium iodide staining (Bender MedSystems). Cells were treated with etoposide (35–100 μM), cisplatin (50 μM), doxorubicin (0.5 μM), or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, 200 ng/ml) for induction of apoptosis. Pan-caspase inhibitor Z-Val-Ala-Asp(Ome)-fluoromethyl ketone (z-VAD-fmk, Bio-Mol) was freshly added to the growth medium 1 h prior to treatment. Staurosporine (100 nM for 6 h) was used as a positive control for induction of apoptosis.

**Plasmids and Luciferase Assay**—Human wild type p53 (wt-p53) encoding pcDNA3.1 plasmid with an N-terminal influenza hemagglutinin epitope tag was used to generate non-cleavable p53 mutants or different p53 fragments. The Stratagene QuickChange site-directed mutagenesis kit was used to mutate candidate aspartate residues to alanine. Treatment of the pcDNA3.1 clone with green fluorescent protein, FLAG, and/or HA epitope tag was used to produce non-cleavable p53 mutants or different p53 fragments cloned in pcDNA3.1 in-frame with green fluorescent protein, FLAG, and/or paramyxo virus of simian virus 5 (V5)–His tag using a TOPO cloning kit (Invitrogen). Luciferase assays were performed following the instructions of the Promega Dual Glo (Stop and Glo) kit with Bax, MDM2, or PG13 promoters (21). Mitochondria-targeted red fluorescent protein (Mito-RFP) plasmid was kindly provided by Prof. P. Nicotera (MRC Toxicology Unit, Leicester, UK).

**In Vitro Transcription-Translation of p53 and In Vitro Caspase Cleavage Assay**—Wild type and alanine-substituted p53 plasmids were in vitro-translated and [35S]methionine-labeled by the Promega TnT-T7-coupled reticulocyte lysate system following the manufacturer's protocol. Substrate cleavage by caspases has also been demonstrated during cell cycle regulation and cellular differentiation (19, 20). However, cleavage of many caspase substrates is probably due to a bystander effect without any apparent biological significance. Although most laboratories report p53 as exclusively nuclear, others ascribe a cytoplasmic function for p53. Since we observed low molecular weight p53-derived proteins following induction of apoptosis, we asked whether p53 could be processed by caspases and whether any of these cleavage products could have an effect on mitochondria.

In this study, we have demonstrated that p53 is a caspase target. Processing of p53 by caspases results in the generation of four fragments, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**ACKNOWLEDGMENTS**

The p53 tumor suppressor protein exerts most of its anti-tumor-igenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis, independent of transcriptional activity. Processing of p53 by caspases results in the generation of four cleavage products, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**EXPERIMENTAL PROCEDURES**

**Cell Culture and Drug Treatments**—Cell lines were grown as suggested by ATCC. Transfections were carried out by using Lipofectamine 2000 reagent (Invitrogen). Apoptosis was assessed by flow cytometry using annexin V-propidium iodide staining (Bender MedSystems). Cells were treated with etoposide (35–100 μM), cisplatin (50 μM), doxorubicin (0.5 μM), or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, 200 ng/ml) for induction of apoptosis. Pan-caspase inhibitor Z-Val-Ala-Asp(Ome)-fluoromethyl ketone (z-VAD-fmk, Bio-Mol) was freshly added to the growth medium 1 h prior to treatment. Staurosporine (100 nM for 6 h) was used as a positive control for induction of apoptosis.

**Plasmids and Luciferase Assay**—Human wild type p53 (wt-p53) encoding pcDNA3.1 plasmid with an N-terminal influenza hemagglutinin epitope tag was used to generate non-cleavable p53 mutants or different p53 fragments. The Stratagene QuickChange site-directed mutagenesis kit was used to mutate candidate aspartate residues to alanine. Treatment of the pcDNA3.1 clone with green fluorescent protein, FLAG, and/or paramyxo virus of simian virus 5 (V5)–His tag using a TOPO cloning kit (Invitrogen). Luciferase assays were performed following the instructions of the Promega Dual Glo (Stop and Glo) kit with Bax, MDM2, or PG13 promoters (21). Mitochondria-targeted red fluorescent protein (Mito-RFP) plasmid was kindly provided by Prof. P. Nicotera (MRC Toxicology Unit, Leicester, UK).

**In Vitro Transcription-Translation of p53 and In Vitro Caspase Cleavage Assay**—Wild type and alanine-substituted p53 plasmids were in vitro-translated and [35S]methionine-labeled by the Promega TnT-T7-coupled reticulocyte lysate system following the manufacturer's protocol. Substrate cleavage by caspases has also been demonstrated during cell cycle regulation and cellular differentiation (19, 20). However, cleavage of many caspase substrates is probably due to a bystander effect without any apparent biological significance. Although most laboratories report p53 as exclusively nuclear, others ascribe a cytoplasmic function for p53. Since we observed low molecular weight p53-derived proteins following induction of apoptosis, we asked whether p53 could be processed by caspases and whether any of these cleavage products could have an effect on mitochondria.

In this study, we have demonstrated that p53 is a caspase target. Processing of p53 by caspases results in the generation of four fragments, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**ACKNOWLEDGMENTS**

The p53 tumor suppressor protein exerts most of its anti-tumor-igenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis, independent of transcriptional activity. Processing of p53 by caspases results in the generation of four cleavage products, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**ACKNOWLEDGMENTS**

The p53 tumor suppressor protein exerts most of its anti-tumor-igenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis, independent of transcriptional activity. Processing of p53 by caspases results in the generation of four cleavage products, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.

**ACKNOWLEDGMENTS**

The p53 tumor suppressor protein exerts most of its anti-tumor-igenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis, independent of transcriptional activity. Processing of p53 by caspases results in the generation of four cleavage products, two of which lack a nuclear localization signal and localize to mitochondria. These mitochondrial p53 fragments induce mitochondrial membrane depolarization in the absence of transcriptional activity.
instructions. For *in vitro* cleavage, proteins were incubated with either 200 nM active caspase-6, -7, or -8 or 20–400 nM recombinant active caspase-3 (18).

**Antibodies and Immunoblot Analysis**—For crude extracts, an equal number of cells were sonicated in 2× H11003 Laemmli buffer and boiled at 95 °C for 5 min. Mitochondria were isolated using the Pierce mitochondria isolation kit (chemical method). Actin and p53 antibodies DO1, 1801, C19, and FL393 were purchased from Santa Cruz Biotechnology. Poly(ADP-ribose) polymerase (PARP) antibody was from Alexis Bio medicals, proliferating cell nuclear antigen antibody was from BD Biosciences, and cytochrome c oxidase-complex IV subunit II (COX II) antibody was from Molecular Probes. The quantitation of bands was performed using NIH-Scion software.

**Immunofluorescence**—H1299 or SaOS-2 cells (10⁵) were plated on coverslips and transfected with full-length p53 (FLp53) or p53 fragments, alone or in combination with mito-RFP. Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline for 30 min. Following fixation, cells were permeabilized for 2 min in phosphate-buffered saline containing 0.1% Triton-X-100, blocked in 2.5% goat serum for 30 min, and incubated with the primary antibody for 1 h. Alexa-488-conjugated secondary antibody was used as recommended by the supplier (Molecular Probes), and the nuclei were counterstained with 4',6-diamidino-2-phenylindole. Slides were analyzed with a confocal laser microscope (ZEISS LSM 510).

**Analysis of Mitochondrial Membrane Depolarization**—Following transfection of HeLa or H1299 cells with relevant plasmids, cells were trypsinized, counted, pelleted, and resuspended in fresh medium (10⁶ cells/ml). After a 25-min recovery in the cell culture incubator, tetramethylrhodamine ethyl ester was added to the cells (50 ng/ml). After a further 5-min incubation, membrane potential was read using a flow cytometer (FACSCalibur, BD Biosciences).

**RESULTS AND DISCUSSION**

*p53 Is Cleaved by Caspases*—During cellular stress, p53 protein levels increase, and this is accompanied by the appearance of several lower and higher molecular weight p53-derived peptides (Fig. 1A). The high molecular weight p53 protein forms have been identified as ubiquitylated forms of full-length p53, whereas some of the low molecular...
p53 Cleavage by Caspases

weight forms are derived from alternative splicing, differential promoter usage, or calpain processing (9, 10, 13).

To investigate the possibility that some of the small p53 protein fragments could be due to caspase cleavage, we incubated recombinant active caspases with in vitro-translated [35S]methionine-labeled p53 protein. Caspase-3, -6, and -7, but not caspase-8, cleaved human p53, revealing several products (Fig. 1B). The cleavage pattern of these caspases was similar, although caspase-3 cleaved p53 more extensively; therefore, we focused our work on p53 cleavage by caspase-3. p53 cleavage by caspase-3 yielded four major products and was evident even with 50 nM active caspase-3 (Fig. 1C). These results demonstrate that different caspases can cleave p53 and that there are more than one cleavage site for caspase 3.

In silico analysis of the p53 protein sequence did not reveal any classical caspase recognition site; therefore, we aimed to locate the cleavage sites by antibody mapping. p53 cleavage products were separated by SDS-PAGE and probed with three different p53 antibodies. With the N-terminal-specific DO1 antibody, we detected two cleavage products (fragments 2 and 3, Fig. 1D). The C-terminal-specific C19 antibody detected only fragments 1 and 4, and the polyclonal FL393 antibody detected all four cleavage products (Fig. 1D). These data suggest that there are two cleavage sites, one located at the N terminus and the other located in the central portion of the protein.

Based on the molecular weights of the fragments and the results obtained by antibody mapping, we focused on two potential sequences, namely 18TFSD21 and 183SDSD186 (Fig. 1E). Wild type and D21A, D186A p53-expressing plasmids were translated in the presence of [35S]methionine and incubated with caspase-3. Cleavage of the D21A mutant resulted in the formation of fragments 2 and 4, whereas only fragment 1 was produced following cleavage of the D186A mutant (Fig. 1E). When both Asp7 and Asp186 residues were mutated, none of the cleavage products was observed. Therefore, fragment 1 corresponds to p53-(22–393), fragment 2 corresponds to p53-(1–186), fragment 3 corresponds to p53-(22–186), and fragment 4 corresponds to p53-(187–393). The cleavage sites are conserved in higher eukaryotes from fish to human (Fig. 1F). Taken together, our data demonstrate the presence of two caspase-3 cleavage sites in p53, at residues Asp21 and Asp186.

p53 Fragments Localize to Mitochondria—To evaluate whether these cleavage products possess a biological function, we generated plasmids harboring either FLp53 or the various fragments with either C- and/or N-terminal tags (Fig. 2A). Following transfection, all fragments were expressed (Fig. 2B), and marked differences were observed in their cellular localization (Fig. 2C). FLp53, p53-(22–393), and p53-(187–393), which contain the nuclear localization signal (22), exhibited a predominant nuclear staining. In contrast, p53-(1–186) and p53-(22–186) were mostly localized to the cytoplasm (Fig. 2C). Co-expression of these fragments with mito-RFP revealed that a portion of p53-(1–186) and p53-(22–186) was localized to mitochondria.

Next we asked whether these p53 fragments have an effect on mitochondria. HeLa cells were transfected with FLp53 or with the four p53...
FIGURE 3. p53 fragments induce transcription-dependent and -independent mitochondrial membrane depolarization. A, HeLa cells were transfected with FLp53 and p53 fragments and processed for tetramethylrhodamine ethyl ester staining after 36 h. Staurosporine (Sts) (100 nM for 6 h) was used as a positive control. Apoptotic cells displayed a decreased signal in the FL2 channel. The number of cells having low FL2 signal were quantified against the whole population. p53-(187–393)-transfected cells gave similar amounts of depolarization as mock (pCDNA)-transfected cells (12 and 14%, respectively). FLp53 exerted the most profound effect on mitochondrial membrane potential (35%); however, the p53-(22–186) and p53-(1–186) fragments localized to the mitochondria also produced membrane depolarization. The p53 fragment, p53-(22–393), showed a 22% loss of the mitochondrial membrane potential. B, p53 induces the transcription from Bax, Mdm2, and PG13 promoters, whereas p53-derived fragments have no transactivation activity on their own, except for p53-(22–393), which retains a weak activity. p53 or p53 fragments were transfected in increasing concentrations as indicated by plus signs. +, 15 ng; ++, 50 ng; or ++++, 100 ng of relative plasmid.
FIGURE 4. Endogenous p53 is cleaved by caspases during apoptosis. A, HCT116 and U2OS cells were treated with etoposide (75 μM), cisplatin (50 μM), or doxorubicin (0.5 μM) for 24 h in the presence or absence of z-VAD-fmk (100 μM). Apoptosis was measured by fluorescence-activated cell sorter analysis for annexin V staining. An equal number of cells were sonicated in Laemmli buffer and subjected to Western blotting for the analysis of p53 processing, caspase-3 and PARP cleavage. The arrows indicate two major p53 cleavage products.
fragments, and mitochondrial membrane potential was analyzed by tetramethylrhodamine ethyl ester staining. 35% of cells showed mitochondrial depolarization with FLp53 (Fig. 3A). The nuclear p53 fragment (p53-(187–393)) and empty vector had no effect on mitochondria (14 and 12% respectively), whereas the other three p53 fragments produced a significant mitochondrial membrane depolarization. p53-(22–393) caused a 22% loss of membrane potential, whereas the fragments that were localized to mitochondria, p53-(1–186) and p53-(22–186), showed 25 and 27% mitochondrial depolarization, respectively. To rule out the possibility that mitochondrial membrane depolarization caused by p53 fragments is through transactivation, we tested the fragments on several p53 target promoters. Luciferase reporter assays with Bac, MDM2, and PG13 promoters demonstrated that p53-(1–186), p53-(22–186), and p53-(187–393) were transcriptionally inactive (Fig. 3B). p53-(22–393) retained a weak transcriptional activity, which may explain the mitochondrial depolarization caused by the overexpression of this fragment (Fig. 3, A and B). Thus, p53-(1–186) and p53-(22–186) cause mitochondrial membrane depolarization independent of p53-dependent transactivation.

Endogenous p53 Is Processed during DNA Damage and TRAIL-induced Apoptosis—We induced apoptosis in HCT116 and U2OS cells by TRAIL or DNA-damaging agents such as etoposide, cisplatin, or doxorubicin to demonstrate the presence of endogenous p53 caspase-cleavage products. In both cell lines, DNA-damaging agents induced apoptosis, as assessed by phosphatidylserine externalization, processing of caspase-3, and PARP cleavage (Fig. 4A, lanes 2, 4, 6, 9, and 11). Apoptosis induced by these agents was associated with the appearance of two p53-related fragments. The C-terminal-specific C19 antibody detected a fragment of ~45 kDa, corresponding to p53-(22–393), whereas the DO1 antibody detected a fragment of ~25 kDa, corresponding to p53-(1–186) (Fig. 4A). Generation of these cleavage products was caspase-dependent as it was blocked with z-VAD-fmk (Fig. 4A, lanes 3, 5, 7, 10, and 12). Although we detected all of the four fragments in vitro, we could not detect p53-(22–186) and p53-(187–393) with any of the p53 antibodies used (DO1, 1801, FL393, and C19) in vivo. Each of these agents also induced the formation of several other p53 forms/fragments, which were not inhibited by z-VAD-fmk (Fig. 4A, indicated by star), suggesting the caspase-independent formation of these products. Caspase-dependent p53 processing was also observed in HCT116 cells when apoptosis was induced by TRAIL (Fig. 4B). However, only the small (p53-(1–186)) fragment was detected. The failure to observe p53-(22–393) may be due to the rapid progression of apoptosis by TRAIL, whereas artificially mutating p53 in residues other than the ones corresponding to p53-(22–393) would be expected to result in p53 accumulation. To evaluate the in vivo kinetics of p53 cleavage, SH-SY5Y cells were treated with etoposide (Fig. 4C). Caspase-dependent cleavage of p53 was detected as early as 4 h and was associated with the appearance of processed caspase-3 and cleaved PARP. Treatment with z-VAD-fmk abolished the processing of p53. These results demonstrate that a fraction of endogenous p53 protein is cleaved by caspases during apoptosis induced either by the intrinsic or by the extrinsic pathways.

To verify that the N-terminal p53 fragment detected by the DO1 antibody in cells (Fig. 4, A–C) is the mitochondrial p53 fragment (p53-(1–186)), we transfected H1299 cells with FLp53 and treated them with cisplatin. Lysates from isolated mitochondria were subjected to Western blotting. The fragment corresponding to p53-(1–186) was detected mostly in the mitochondrial fraction (Fig. 4D). Purity of the subcellular fractions was assessed by actin, proliferating cell nuclear antigen, and COX II Western blots. We could not detect the p53-(22–393) fragment in either of the fractions by using the C19 antibody. The kit we used was exclusively for mitochondria isolation (Pierce mitochondria isolation kit). Therefore, we believe that this p53 fragment was lost during the mitochondrial purification procedure. After having detected the caspase-generated p53 fragment in mitochondria by overexpression of FLp53, we wanted to verify the presence of the mitochondrial p53 fragment in cells harboring endogenous wild type p53 following caspase activation. Apoptosis was induced by TRAIL or etoposide treatment in HCT116 and SH-SY5Y cells, respectively, and assessed by caspase-3 processing and PARP cleavage, using non-fractionated lysates (data not shown). Supporting our overexpression data, we observed the endogenous fragment corresponding to p53-(1–186) predominantly in the mitochondrial fraction (Fig. 4E). This suggests that the p53-(1–186) detected in cells undergoing apoptosis is mostly mitochondrial and that this fragment localizes to mitochondria independent of the induction pathway of apoptosis, i.e., by activation of the extrinsic or the intrinsic pathway. Therefore, by using different drugs in cell lines of different origin, we observed the same effect, providing evidence to support the generality of this phenomenon that cleavage of p53 and localization of the cleavage product to mitochondria is a common occurrence.

Our results suggest that although most of the apoptotic activity of p53 relies on its transcription activity, p53 protein can contribute to the apoptotic process directly following caspase activation. To ascertain the approximate contribution of caspase cleavage-dependent activities of p53 to apoptosis, we compared the apoptotic activities of wtp53, D21A, and D186A non-cleavable mutants. As our initial experiments showed that the non-cleavable mutants are potentially more apoptotic than wtp53 (data not shown), we analyzed the transcriptional activities of these mutants. We observed that both of the non-cleavable mutants are transcriptionally active on the Bac and MDM2 promoters (Fig. 5A). Also, our attempts to generate stable cell lines expressing these mutants yielded very few colonies as compared with wtp53, with no protein expression from any (0 colonies for D186A and D21A, as compared with 10 colonies expressing wtp53, data not shown). Interestingly, most naturally occurring mutations inhibit the transcriptional activity of p53, whereas artificially mutating p53 in residues other than the ones observed in tumors may even result in an enhanced transcriptional activity (23). In parallel with these observations, we found that Asp71 and Asp186 mutations are represented very rarely (less than 12 times among 14,000 p53 mutations) in the International Agency for Research on Cancer p53 tumor mutation data base (24).
To characterize the importance of p53 cleavage on apoptosis as well as excluding any transcriptional activity, we used naturally occurring p53 mutants. 10% of all p53 mutations are at codons 248 (R → (W/Q)) and 249 (R → S), resulting in the formation of transcription-deficient p53. Therefore, we generated p53 plasmids with these codon substitutions, with or without D186A. We expressed these p53 plasmids in p53-null H1299 cells and induced apoptosis with cisplatin. Although the p53 mutants were cleaved (Fig. 5B), none of the D186A mutants were processed (data not shown). As the D186A mutant is transcriptionally active (Fig. 5A), we assayed the transcriptional activities of these mutants and their non-cleavable derivatives. We observed that all of them are transcriptionally inactive (data not shown).

To demonstrate the impact of caspase cleavage of p53 on apoptosis, we overexpressed wt-p53, naturally occurring p53 mutants, and non-cleavable naturally occurring p53 mutants in H1299 cells. 36 h after transfection, we treated cells with staurosporine (100 nM) for 6 h and analyzed the cells for mitochondrial membrane depolarization. We observed that mutant p53 induces a greater loss in mitochondrial membrane potential than the non-cleavable counterpart following induction of apoptosis (Fig 5C). Wt-p53 was clearly more potent at inducing mitochondrial membrane depolarization in the presence or absence of an apoptotic stimulus than any of the mutants (Fig 5C). Our observations provide evidence that the apoptotic function of p53 is mostly transcription-dependent, but there is also a small but significant proportion that is transcription-independent and acquired after caspase activation, possibly to promote cells toward the point of no return.

Our results suggest that following caspase activation, p53 gains a transcription-independent function to reinforce apoptosis. This may lead to the formation of a positive feedback loop in which p53 accumulation induces caspase activation, resulting in p53 cleavage and promotion of apoptosis. Moreover, mutant p53 proteins that are observed in more than 50% of all tumors can also be targets of caspases, suggesting that they may still be able to induce mitochondrial depolarization, attributing a wild type p53 function to mutant p53.

Acknowledgments—We thank Dr. Xiaoming Sun for the active caspases, Dr. Nick Harper for TRAIL, and Drs. M. Rossi and M. J. Pinkoski for critical reading of the manuscript.

REFERENCES
1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991) Science 253, 49–53
2. Vousden, K. H., and Prives, C. (2005) Cell 120, 7–10
3. Vousden, K. H., and Lu, X. (2002) Nat. Rev. Cancer 2, 594–604
4. Oren, M. (2003) Cell Death Differ. 10, 431–442
5. Chipuk, J. E., and Green, D. R. (2003) J. Clin. Immunol. 23, 355–361
6. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E., and George, D. L. (2004) Nat. Cell Biol. 6, 443–450
7. Mihara, M., Erster, S., Zaika, A., Pettenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. (2003) Mol. Cell 11, 577–590
8. Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., and Green, D. R. (2004) Science 303, 1010–1014
9. Brooks, C. L., and Gu, W. (2003) Curr. Opin. Cell Biol. 15, 164–171
10. Kubbata, M. H., and Vousden, K. H. (1997) Mol. Cell. Biol. 17, 460–468
11. Pariati, M., Carillo, S., Molinari, M., Salvat, C., Debussche, L., Bracco, L., Milner, J., and Pecchaczyk, M. (1997) Mol. Cell. Biol. 17, 2806–2815
12. Courtiou, S., Verhaegh, G., North, S., Luciani, M. G., Lassus, P., Hibner, U., Oren, M., and Hainaut, P. (2002) Oncogene 21, 6722–6728
13. Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., and Lane, D. P. (2005) Genes Dev. 19, 2122–2137
14. Fischer, U., Janicke, R. U., and Schulze-Osthoff, K. (2003) Cell Death Differ. 10, 76–100
15. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cell 94, 491–501
16. Ricci, J. E., Munoz-Pinedo, C., Fitzgerald, P., Bailly-Maitre, B., Perkins, G. A.,...
Yadava, N., Scheffler, I. E., Ellisman, M. H., and Green, D. R. (2004) Cell 117, 773–786
17. Sakahira, H., Enari, M., and Nagata, S. (1998) Nature 391, 96–99
18. Sun, X. M., Butterworth, M., MacFarlane, M., Dubiel, W., Ciechanover, A., and Cohen, G. M. (2004) Mol. Cell 14, 81–93
19. Arama, E., Agapite, J., and Steller, H. (2003) Dev. Cell 4, 687–697
20. Kennedy, N. J., Kataoka, T., Tschoopp, J., and Budd, R. C. (1999) J. Exp. Med. 190, 1891–1896
21. Blagosklonny, M. V., Giannakakou, P., Romanova, L. Y., Ryan, K. M., Vousden, K. H., and Fojo, T. (2001) Carcinogenesis 22, 861–867
22. Addison, C., Jenkins, J. R., and Sturzbecher, H. W. (1990) Oncogene 5, 423–426
23. Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., and Ishioka, C. (2005) Cancer Res. 65, 2108–2114
24. Soussi, T., Dehouche, K., and Beroud, C. (2000) Hum. Mutat. 15, 105–113

p53 Cleavage by Caspases

MAY 12, 2006 • VOLUME 281 • NUMBER 19 • JOURNAL OF BIOLOGICAL CHEMISTRY 13573